[go: up one dir, main page]

WO2000068363A3 - Variantes de l'elastase et substrats - Google Patents

Variantes de l'elastase et substrats Download PDF

Info

Publication number
WO2000068363A3
WO2000068363A3 PCT/US2000/006692 US0006692W WO0068363A3 WO 2000068363 A3 WO2000068363 A3 WO 2000068363A3 US 0006692 W US0006692 W US 0006692W WO 0068363 A3 WO0068363 A3 WO 0068363A3
Authority
WO
WIPO (PCT)
Prior art keywords
elastase
variants
substrates
histidine
amino acid
Prior art date
Application number
PCT/US2000/006692
Other languages
English (en)
Other versions
WO2000068363A2 (fr
Inventor
Paul J Carter
Acqua William Dall
Maria Rodriques
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU49709/00A priority Critical patent/AU4970900A/en
Publication of WO2000068363A2 publication Critical patent/WO2000068363A2/fr
Publication of WO2000068363A3 publication Critical patent/WO2000068363A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6448—Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des variantes de l'élastase présentant une ou plusieurs substitutions d'acides aminés à des positions sélectionnées d'une élastase précurseur. En particulier, un reste d'histidine de site actif, correspondant à l'histidine 43 présente dans l'élastase neutrophile humaine, peut être substitué par un acide aminé présentant un volume inférieur à celui de l'histidine. Dans des modes de réalisation préférés, les variantes de l'élastase selon l'invention présentent un substrat spécifique remarquable pour ce qui est des substrats contenant les restes d'histidine à la position correspondant à deux restes d'acides aminés du côté N-terminal du site de coupure. L'invention concerne également des substrats préférés pour des variantes de l'élastase. Les variantes de l'élastase et les substrats décrits dans la présente invention sont utilisés pour diverses applications thérapeutiques et non thérapeutiques.
PCT/US2000/006692 1999-05-05 2000-05-04 Variantes de l'elastase et substrats WO2000068363A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49709/00A AU4970900A (en) 1999-05-05 2000-05-04 Elastase variants and substrates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13264099P 1999-05-05 1999-05-05
US60/132,640 1999-05-05

Publications (2)

Publication Number Publication Date
WO2000068363A2 WO2000068363A2 (fr) 2000-11-16
WO2000068363A3 true WO2000068363A3 (fr) 2001-02-15

Family

ID=22454939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006692 WO2000068363A2 (fr) 1999-05-05 2000-05-04 Variantes de l'elastase et substrats

Country Status (2)

Country Link
AU (1) AU4970900A (fr)
WO (1) WO2000068363A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307478A1 (fr) * 1987-03-05 1989-03-22 Toray Industries, Inc. Protease de serine et gene de protease de serine
JPH06303984A (ja) * 1993-04-19 1994-11-01 Japan Tobacco Inc 組換えｄｎａ、それによって形質転換された酵母及びそれを用いたアクアライシンｉの製造方法
WO1998024886A1 (fr) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Protease issue de mastocytes clivant le fibrogene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307478A1 (fr) * 1987-03-05 1989-03-22 Toray Industries, Inc. Protease de serine et gene de protease de serine
JPH06303984A (ja) * 1993-04-19 1994-11-01 Japan Tobacco Inc 組換えｄｎａ、それによって形質転換された酵母及びそれを用いたアクアライシンｉの製造方法
WO1998024886A1 (fr) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Protease issue de mastocytes clivant le fibrogene

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DALL'ACQUA WILLIAM ET AL: "Elastase substrate specificity tailored through substrate-assisted catalysis and phage display.", PROTEIN ENGINEERING, vol. 12, no. 11, November 1999 (1999-11-01), pages 981 - 987, XP000960584, ISSN: 0269-2139 *
DAMAK S ET AL: "EXPRESSION OF THE HUMAN NEUTROPHIL ELASTASE GENE IN THE LUNGS OF TRANSGENIC MICE", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT,US,A.R. LISS, NEW YORK, NY, no. SUPPL, 3 April 1992 (1992-04-03), pages 40, XP002910419, ISSN: 0733-1959 *
DATABASE WPI Section Ch Week 199503, Derwent World Patents Index; Class B04, AN 1995-018277, XP002152475 *
EDER JORG ET AL: "Folding of subtilisin BPN': Characterization of a folding intermediate.", BIOCHEMISTRY, vol. 32, no. 1, 1993, pages 18 - 26, XP000960578, ISSN: 0006-2960 *
REHEMTULLA A ET AL: "REGULATION OF PACE PROPEPTIDE-PROCESSING ACTIVITY REQUIREMENT FOR A POST-ENDOPLASMIC RETICULUM COMPARTMENT AND AUTOPROTEOLYTIC ACTIVATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 89, no. 17, 1992, 1992, pages 8235 - 8239, XP000960579, ISSN: 0027-8424 *
TAKAHASHI H ET AL: "STRUCTURE OF THE HUMAN NEUTROPHIL ELASTASE GENE", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 263, no. 29, 15 October 1988 (1988-10-15), pages 14739 - 14746, XP002911716, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2000068363A2 (fr) 2000-11-16
AU4970900A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
WO2000077027A3 (fr) Composes
WO2000076971A3 (fr) Composes
NZ606504A (en) Modified proteases that inhibit complement activation
AU3960400A (en) Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
IL140338A0 (en) Amino acid derivatives which inhibit dipeptidyl peptidase iv and pharmaceutical compositions containing the same
CA2000342A1 (fr) Nouveau inhibiteurs de la peptidase
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
AU2001272995A1 (en) Stable liquid enzyme compositions with enhanced activity
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
EP1419785A4 (fr) Medicaments contenant un inhibiteur de la chymase et un inhibiteur de l'ace comme principes actifs
CA2388476A1 (fr) Derives d'imidazo-5-yl-amine bicycliques
WO2003010291A3 (fr) Traitement de troubles concernant les cellules immunitaires et les cellules b
WO2003011222A3 (fr) Inhibiteurs de la thrombine
AU2001262732A1 (en) Inhibitor for enzyme having two divalent metal ions as active centers
WO2000001826A3 (fr) Variants stabilises d'inhibiteur de subtilisine de streptomyces
AU8184301A (en) Inhibitors for the blood-clotting factor xa
WO2000068363A3 (fr) Variantes de l'elastase et substrats
ATE307494T1 (de) Zusammensetzung, welche pektinmethylesterase und zwei substrate beinhaltet
WO2001096540A3 (fr) Exosite de la protease de l'hepatite c servant a la mise au point d'inhibiteurs
PH12013502021A1 (en) Platelet aggregation inhibitor composition
HK1052315A1 (zh) 抗血栓形成合成物
WO2000061171A3 (fr) Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes
WO2004024765A8 (fr) Structure de cristal d'une enzyme de conversion de l'angiotensine (ace) et ses utilisations
WO2003097664A3 (fr) Inhibiteurs de cysteine proteases a base de propeptides
WO2001000189A3 (fr) Combinaison d'inhibiteurs de mtp et principes actifs agissant sur le metabolisme et leur utilisation dans les medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP